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AbsTrACT
Objective We characterised the clinical course, 
treatment and outcomes in 59 patients with relapsing 
myelin oligodendrocyte glycoprotein (MOG) antibody-
associated demyelination.
Methods We evaluated clinical phenotypes, annualised 
relapse rates (aRR) prior and on immunotherapy 
and expanded Disability status scale (eDss), in 218 
demyelinating episodes from 33 paediatric and 26 adult 
patients.
results The most common initial presentation in 
the cohort was optic neuritis (ON) in 54% (bilateral 
(BON) 32%, unilateral (UON) 22%), followed by acute 
disseminated encephalomyelitis (aDeM) (20%), which 
occurred exclusively in children. ON was the dominant 
phenotype (UON 35%, BON 19%) of all clinical 
episodes. 109/226 (48%) MRIs had no brain lesions. 
patients were steroid responsive, but 70% of episodes 
treated with oral prednisone relapsed, particularly at 
doses <10 mg daily or within 2 months of cessation. 
Immunotherapy, including maintenance prednisone 
(p=0.0004), intravenous immunoglobulin, rituximab and 
mycophenolate, all reduced median aRRs on-treatment. 
Treatment failure rates were lower in patients on 
maintenance steroids (5%) compared with non-steroidal 
maintenance immunotherapy (38%) (p=0.016). 58% 
of patients experienced residual disability (average 
follow-up 61 months, visual loss in 24%). patients with 
ON were less likely to have sustained disability defined 
by a final eDss of ≥2 (OR 0.15, p=0.032), while those 
who had any myelitis were more likely to have sustained 
residual deficits (OR 3.56, p=0.077).
Conclusion Relapsing MOG antibody-associated 
demyelination is strongly associated with ON across all 
age groups and aDeM in children. patients are highly 
responsive to steroids, but vulnerable to relapse on 
steroid reduction and cessation.
INTrOduCTION
Myelin oligodendrocyte glycoprotein (MOG) is a 
component of myelin expressed exclusively in the 
central nervous system (CNS).1 2 Using cell-based 
assays that preserve the conformational structure 
of full-length human MOG, antibodies targeting 
MOG have been recently identified in both children 
and adults with demyelination including acute 
disseminated encephalomyelitis (ADEM), optic 
neuritis (ON) and transverse myelitis (TM), with 
some patients fulfilling revised diagnostic criteria 
for aquaporin-4 (AQP4) antibody-negative neuro-
myelitis optica spectrum disorder (NMOSD).3–8 
There is increasing evidence that some patients 
have a relapsing course.6 9–11 
Accurate diagnosis of the demyelinating aetiology is 
essential as treatment options vary between multiple 
sclerosis (MS) and NMOSD. While MS is frequently 
treated with disease-modifying immunomodulatory 
therapy, some agents used in MS such as interferon, 
natalizumab and fingolimod have been shown to not 
benefit or have a detrimental impact in AQP4 anti-
body-positive NMOSD.12–14 Immunosuppressants 
such as azathioprine, mycophenolate and rituximab 
all reduce relapse rates in AQP4 antibody-positive 
NMOSD.15–17 Data regarding the efficacy of immu-
notherapy in patients with MOG antibodies is limited. 
Herein, we detail the response to specific immuno-
therapies in a large multicentre cohort of paediatric 
and adult patients with relapsing MOG antibody-as-
sociated demyelination.
MeThOds
study design, patient recruitment and antibody 
testing
Patients were classified as paediatric (≤16) or adult 
(>16) based on age at disease onset. All serum 
samples were tested for MOG antibodies in a single 
centre using a flow cytometry live cell-based assay 
as previously described.6 10 We identified 61 patients 
with relapsing demyelination (≥2 episodes) for 
whom detailed clinical information was available, 
from neurology, neuroimmunology and neuro-oph-
thalmology clinics in 25 centres in Australasia 
(Australia n=22, New Zealand n=2, Singapore 
n=1). An acute episode was defined as a new neuro-
logical deficit lasting at least 24 hours.17 A relapse 
was any new CNS symptom/sign lasting >24 hours 
in the absence of other causes, and supported 
clinically or radiologically.15 This included neuro-
logical symptoms/signs that occurred during the 
course of treatment weaning, but were distinct 
from the initial presentation and separated by a 
period of recovery/improvement. Two paediatric 
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patients were excluded due to being lost to follow-up. In total, 
59 patients (paediatric n=33, adult n=26) were included. Data 
was retrospectively collected by SR (adult) and RCD (paedi-
atric) through telephone interviews with each patient’s neurolo-
gist, using a structured questionnaire created for this study (see 
online supplementary appendix 1). All patients had a minimum 
of 12 months of follow-up.
Therapeutic efficacy
We calculated annualised relapse rates (ARR) for each patient as 
the number of relapses/year pretreatment and on-treatment.18 19 
Pretreatment ARRs were calculated after excluding the index 
episode, to avoid an inaccurately high value.18 19 All ARRs 
were calculated only if the period of time being assessed was 
≥6 months. We calculated the cumulative cohort ARR for each 
treatment (total number of relapses in cohort/total patient-years 
on each treatment). Patients were included in calculations of 
ARR if they fulfilled the following criteria.
Corticosteroids
Pulsed intravenous methylprednisolone (dose 20–30 mg/kg/day 
for children, 500 mg–1 g/day for adults, over 3–5 days) and/or a 
taper of oral prednisone (starting dose 1–2 mg/kg/day in children 
and 1 mg/kg in adults) with variable tapering durations, based 
on individual clinician preference. Patients were classified as 
being on ‘maintenance corticosteroids’ if they were given oral 
corticosteroids after second or further demyelinating episodes 
at daily doses >10 mg for patients >40 kg in weight, and >5 mg 
for patients ≤40 kg in weight.
Intravenous immunoglobulin
An induction course dose of 2 g/kg, and subsequent monthly 
doses of 1 g/kg/infusion.
Steroid-sparing immunosuppression
Treatment with mycophenolate, azathioprine or methotrexate at 
adequate doses for weight.15
Rituximab
ARR was calculated for 6 months after rituximab infusion. 
Rituximab failure was defined as a relapse occurring between 
2 weeks and 6 months after treatment. A ‘repopulation relapse’ 
was a relapse associated with B-cell repopulation (CD19 count 
≥10×106 cells/L).19
Outcomes
Patient outcomes were characterised using the Expanded 
Disability Status Scale (EDSS).20 Recovery from each demyelin-
ating episode was additionally classified as complete, partial or 
no recovery. Complete recovery included a normal neurological 
examination. Residual deficits were classified including visual 
impairment (with reduced visual acuity), sensory, motor, cogni-
tive and/or sphincter dysfunction and epilepsy.
standard protocol approval and patient consent
Ethics and research protocol approval (NEAF 12/SCHN/395) was 
granted by the individual ethics committees for all participating 
hospitals. Informed consent was obtained from all patients.
statistical analyses
Patient and clinical characteristics were described by frequen-
cies and percentages for categorical variables; and mean, median 
and range for continuous variables. Predictors of categorical 
outcomes were examined using Χ2 tests, as well as univariable 
and multivariable logistic regression models and described by 
OR and 95% CIs. Comparisons between groups of patients 
were performed using Χ2 tests and Wilcoxon rank-sum or Krus-
kal-Wallis tests. ARRs were tested using the Wilcoxon signed 
rank test to examine whether ARRs decreased during treatment. 
Treatment failure rates were described with 95% CIs using the 
Wilson method. Comparison in treatment failure rates between 
maintenance steroids and non-steroidal immunosuppression 
was performed using Fisher’s exact test. Figures were generated 
using Prism Software V.6.0 (GraphPad Software, La Jolla, Cali-
fornia, USA) and Adobe Illustrator CS6 (Adobe Systems, San 
Jose, California, USA).
resulTs
Clinical characterisation
We identified 59 patients (40 female, 19 male) with relapsing 
MOG antibody-associated demyelination, with a total of 218 
episodes. Patients were followed up for an average of 61 months 
(median 45, range 12–288) (table 1, online supplementary tables 
1 and 2).
The median age of onset for the total cohort was 12 years 
(mean 21 range 1–74), in children aged 6 years (mean 7, range 
1–16), and in adults aged 37 years (mean 40, range 18–74). Forty-
three out of fifty-nine (73%) patients were Caucasian. Forty-
seven per cent had an infectious prodrome (including myalgia, 
fevers or preceding symptoms consistent with respiratory infec-
tion) in the month prior to their first episode. Two patients had 
a vaccination within 3 weeks prior to an episode. Three patients 
had their first presentation (n=2) or relapse (n=1) ≤4 months 
post partum. Four patients had coexistent autoimmunity (type 1 
diabetes mellitus and Hashimoto’s thyroiditis, elevated thyroid 
antibodies, Henoch-Schönlein purpura and prior LGI1 anti-
body-positive encephalitis). Twenty out of fifty-nine patients 
had two demyelinating episodes, and 39/59 had ≥3 (see online 
supplementary figure 1A and appendix 2).
There was a difference in clinical phenotypes on first presen-
tation between children and adults (P=0.006). The most 
common presenting phenotype in the total cohort was ON 
(54%) (bilateral ON (BON) 32%, unilateral ON (UON) 22%) 
(figure 1A). ADEM (2013 criteria)21 was the most common 
presentation in children (36%), followed by BON (24%) and 
UON (15%). Adults presented primarily with ON 73% (BON 
42%, UON 31%). TM was less common. Isolated seizures with 
mild encephalopathy and subtle inflammatory changes in CSF 
or radiology, but in the absence of clinical and radiological 
features of ADEM,21 were present in two children. Mixed 
presentations were common (see online supplementary table 
3). Seven out of fifty-nine patients (five adults and two chil-
dren) had simultaneous ON+longitudinally extensive trans-
verse myelitis episodes consistent with the classical description 
of Devic’s disease.
When evaluating the clinical phenotype of all 218 episodes in 
the cohort, ON remained dominant (figure 1B). UON (35%) was 
most common, followed by BON (19%). ADEM was common in 
children (15%), but rare in adults (2%). TM was less common in 
the whole cohort (11%), and more prevalent in adults.
Relapsing ON was the main relapsing clinical syndrome in 
the total cohort (29%), followed by NMOSD (2015 criteria)8 
(25%) (table 1). ADEM was present at some point in the disease 
course in 31% of the whole cohort; including 52% of children 
and 4% of adults, which was statistically different (p<0.0001). 
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Fifty-one out of fifty-nine patients had one or more episodes 
involving ON. Funduscopy results were available in 30/51 
patients and 27/30 (90%) had visible optic nerve head swelling 
with the ON (9/11 (82%) children and 18/19 (95%) adults).
This study identified some uncommon clinical phenotypes 
associated with MOG antibodies. Some patients presented with 
sensory symptoms (predominantly lower limb paraesthesia) that 
were steroid responsive, in the absence of radiological myelitis. 
One adult patient with relapsing BON presented with recurrent 
subacute cognitive decline that was reversible with steroids and 
immunotherapy. It is conceivable that she had concurrent auto-
immune encephalitis; however, testing for neuronal cell surface 
antibodies was negative, and she did not have seizures.
Cerebrospinal fluid analysis
CSF at initial presentation was available in 49/59 patients; 28/48 
(58%) had a mononuclear lymphocytic pleocytosis (≥5 mononu-
clear cellsx106/L) but only 18/49 (37%) had an elevated protein 
level (>0.40 g/L for children, >0.45 g/L for adults). Forty-five 
patients were tested for intrathecal oligoclonal bands and only 
5/45 (11%) were positive (table 1); 14/49 patients had normal 
routine CSF analysis.
MrI findings
MRI brain scans were reviewed to confirm whether the patients 
fulfilled 2010 revised McDonald criteria radiologically for 
dissemination in space and time at the time of each scan.22 One 
Table 1 Cohort summary of relapsing paediatric and adult MOG antibody-positive patients: clinical and laboratory characteristics
Clinical and laboratory characteristics Total cohort (n=59) Paediatric patients (n=33) Adult patients (n=26) P value*
Age at onset (years)
Mean; median (range)
21; 12 (1-74) 7; 6 (1–16) 40; 37 (18-74)   NA
Gender
F:M (% female)
40:19 (68%) 22:11 (67%) 18:8 (69%) 0.834
Ethnicity Caucasian 43/59 (73%) 24/33 (73%) 19/26 (73%) 0.976†
South Asian 5/59 (8.5%) 1/33 (3%) 4/26 (15%)
East Asian 4/59 (6.7%) 3/33 (9%) 1/26 (4%)
Pacific Islander 3/59 (5%) 2/33 (6%) 1/26 (4%)
Middle Eastern 2/59 (3.4%) 1/33 (3%) 1/26 (4%)
Aboriginal 2/59 (3.4%) 2/33 (6%) 0/26 (0%)
Presence of a preceding infectious prodrome 27/57 (47%) 17/33 (52%) 10/24 (42%) 0.462
Presenting phenotype ADEM 12/59 (20%) 12/33 (36%) 0/26 (0%) 0.006
BON 19/59 (32%) 8/33 (24%) 11/26 (42%)
UON 13/59 (22%) 5/33 (15%) 8/26 (31%)
Other 15/59 (26%) 8/33 (24%) 7/26 (27%)
EDSS at initial presentation
Mean; median (range)
5.1; 5 (1–9.5) 5.6; 5 (2–9.5) 4.4; 4 (1–8.5) 0.025
CSF lymphocytic pleocytosis at initial presentation 28/48 (58%) 19/29 (66%) 9/19 (47%) 0.212
CSF protein elevation at initial presentation 18/49 (37%) 11/30 (37%) 7/19 (37%) 0.990
Presence of intrathecal oligoclonal bands at initial presentation 5/45 (11%) 2/27 (7%) 3/18 (17%) 0.333
Relapsing syndromic classification‡ Relapsing ON 17/59 (29%) 6/33 (18%) 11/26 (42%)
NMOSD 15/59 (25%) 7/33 (21%) 8/26 (31%)
ADEM-ON 4/59 (7%) 4/33 (12%) 0%
ADEM-LETM 2/59 (3%) 2/33 (6%) 0%
ADEM-ON-cerebellar 2/59 (3%) 2/33 (6%) 0%
ADEM-brainstem 2/59 (3%) 2/33 (6%) 0%
UON-short TM 2/59 (3%) 0% 0%
Other relapsing 
presentations
15/59 (25%) 10/33 (30%) 7/26 (27%)
Total number of demyelinating episodes
Mean; median (range)
3.7; 3 (2–10) 3.4; 3 (2–8) 4; 3 (2–10) 0.687
Presence of ADEM at some point in clinical course 18/59 (31%) 17/33 (52%) 1/26 (4%) <0.0001
Fulfills 2015 NMOSD criteria 15/59 (25%) 7/33 (21%) 8/26 (31%) 0.403
Fulfills revised McDonald criteria for MS 9/59 (15%) 6/33 (18%) 3/26 (12%) 0.481
Follow-up duration (months)
Mean; median (range)
61; 45 (12–288) 66; 63 (12–206) 54; 39 (12–288) 0.225
EDSS at latest clinical follow-up
Mean; median (range)
1.29; 1 (0–5.5) 1.08; 1 (0–3.5) 1.56; 1.25 (0–5.5) 0.349
*P values compare differences between paediatric-onset and adult-onset demyelination in this cohort.
†Ethnicity was statistically analysed as Caucasian vs non-Caucasian ethnicity.
‡P values were not calculated when analysing differences between children and adults in this row due to multiple comparison groups of smaller numbers. Breakdown of ‘other 
relapsing presentations’ in the total cohort include: ADEM-cerebellar 1/59 (2%), ADEM-brainstem-cerebellar 1/59 (2%), relapsing TM 1/59 (2%), ON-TM-brainstem 1/59 (2%), 
other 11/59 (19%); in the paediatric cohort: ON-TM 1/33 (3%), ADEM-cerebellar 1/33 (3%), ADEM-brainstem-cerebellar 1/33 (3%), other 7/33 (21%); in the adult cohort: ON-TM 
1/26 (4%), relapsing TM 1/26 (4%), ON-TM-brainstem 1/26 (4%), other 4/26 (15%). A detailed description of ‘other’ presentations is supplied in online supplementary table 3.
ADEM, acute disseminated encephalomyelitis; BON, bilateral ON; CSF, central nervous system; EDSS, Expanded Disability Status Scale; LETM, longitudinally extensive transverse 
myelitis; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; ON, optic neuritis; UON, unilateral ON; TM, 
transverse myelitis.
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Figure 1 The clinical phenotype and steroid response in relapsing MOG antibody-associated demyelination. (a) Illustration of the clinical phenotype at 
first presentation of all patients in the cohort, with a breakdown reflecting the distribution of each clinical phenotype in the paediatric age group (0–16 years 
at disease onset), and adult group (>16 years at disease onset). (B) Illustration of the clinical phenotype at all presentations (n=218, initial presentation plus 
relapses) in the cohort, with a breakdown reflecting the distribution of each clinical phenotype in the paediatric and adult group. (c) an illustration of the 
number of relapses that occurred during tapering oral prednisone (and the dose of prednisone at which these relapses occurred), or following the cessation 
of an oral prednisone taper (and the time frame at which these relapses occurred). aDeM, acute disseminated encephalomyelitis; BON, bilateral optic 
neuritis; LeTM, longitudinally extensive transverse myelitis; TM, transverse myelitis; UON, unilateral optic neuritis.
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hundred thirty-one MRIs were performed within 1 month of a 
demyelinating episode, and 58/131 (44%) of these demonstrated 
no brain lesions; 54/58 of normal brain scans were performed 
during isolated ON and/or TM. Only 11/131 acute brain MRIs 
fulfilled radiological McDonald criteria in seven patients. Nine-
ty-six brain MRIs were performed during an asymptomatic 
recovery period (≥3 months following presentation); 52/96 
(54%) of asymptomatic MRIs had no brain lesions; 37/96 (39%) 
had residual changes and only 7/96 (7%) had new asymptomatic 
lesions. These seven MRIs belonged to six patients, and only one 
out of six patients fulfilled revised McDonald criteria for MS. 
Two of these six patients had follow-up scans, which showed no 
new lesions and partial (n=1) or complete (n=1) resolution of 
previous lesions. Four out of six patients are yet to have further 
follow-up radiology and have been clinically asymptomatic.
Acute corticosteroid usage and risk of relapse
Treatment data were available for 191/218 episodes; 181/191 
episodes were treated with corticosteroids; 35/181 episodes 
were treated with intravenous methylprednisolone alone and 
146/181 episodes were treated with oral steroids (following 
intravenous methylprednisolone, n=116; or solely as an oral 
taper, n=30). The median duration of the oral taper was 1.62 
months. Following the 146 episodes treated with oral predniso-
lone taper, there were 103 subsequent episodes, most of which 
occurred towards the end of the taper (n=41 episodes; mean 
dose of oral prednisone at relapse 11.5 mg, median 10 mg, 
range 1.25–60 mg), or shortly after prednisone cessation (n=62 
episodes; median duration after prednisone cessation 2 months, 
range 0–62) (figure 1C). The median length of a planned steroid 
taper was 1.5 months (mean 3, range 0.25–24) for all episodes 
followed by a relapse, compared with 5 months (mean 6.9, range 
0.75–26) for all episodes not followed by a relapse.
Maintenance treatment efficacy
The ARR pretreatment, on-treatment and post-treatment; cumu-
lative cohort ARR and failure rates for each therapeutic agent 
are summarised in table 2 (all therapy trialled in each patient 
is detailed in online supplementary table 4). Only treatments 
with ≥5 patients who fulfilled inclusion criteria are included. 
All treatments were associated with a reduction in ARR on-treat-
ment, with maintenance prednisone having the lowest treatment 
failure rate.
Twenty patients received maintenance oral prednisone for 
≥6 months and were included in ARR calculations (figure 2A, 
table 2); 1/20 (5%) experienced treatment failure.
Seven out of fourteen patients given IVIg fulfilled inclusion 
criteria for maintenance therapy (figure 2B). Three patients had 
six relapses while on adequate treatment with IVIg. Three out 
of seven (43%) experienced treatment failure. Three relapses 
in two patients occurred while weaning IVIg doses (n=2) or 
increasing dosing intervals (n=1).
Sixteen out of seventeen patients given mycophenolate 
fulfilled inclusion criteria for maintenance therapy (figure 2C), 
with a median duration of treatment of 15 months (range 6–37 
months). Eight patients experienced 10 relapses. Seven out of 
sixteen (44%) experienced treatment failure. Four out of ten 
relapses occurred during concomitant prednisone taper. Seven 
out of ten relapses occurred within the first year of mycopheno-
late treatment. One patient relapsed 1 month following myco-
phenolate cessation.
Six out of eight patients given rituximab fulfilled inclusion 
criteria (figure 2D). Three out of six patients were redosed (four T
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Figure 2 Disease activity of myelin oligodendrocyte glycoprotein antibody-positive patients on immunosuppressive therapy. (a) Depictions of the clinical 
course and disease activity in patients who underwent therapy with maintenance prednisone. In patients who had more than two courses of maintenance 
prednisone lasting ≥6 months each, the green lines depict the duration of each course of maintenance corticosteroid therapy. Depictions of the clinical 
course and disease activity in patients who underwent therapy with monthly intravenous immunoglobulin (IVIg) (B), mycophenolate (c) and rituximab (D). 
(e) Illustration of response to switched therapy in the event of side effects (patient 46 azathioprine to mycophenolate), treatment failure of the initial agent 
(patient 38 mycophenolate to rituximab, patient 58 methotrexate to rituximab, patient 39 methotrexate to mycophenolate, patient 8 mycophenolate to 
monthly IVIg and patient 57 azathioprine to mycophenolate), or after exceeding the maximum recommended cumulative dose of the first agent (patient 33 
cyclophosphamide to azathioprine). all therapy (or switched therapy) commenced at time point 0. The magenta lines represent a demyelinating episode. The 
purple squares represent time of switched treatment cessation. The orange circles represent time of latest clinical follow-up. The blue arrows represent timing 
of rituximab dosing.
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courses in one patient, and three courses each for two patients). 
Treatment failure occurred in one out of six (17%) patients with 
two relapses (1 and 3 months after dosing) despite B-cell deple-
tion. Three patients had B-cell repopulation relapses >6 months 
after treatment and were redosed with rituximab. Two out of 
six patients remained relapse free following the first infusion of 
rituximab and have not been retreated.
Treatment failure rates were lower in patients on mainte-
nance steroids (1/20, 5%) compared with patients on trials of 
non-steroidal maintenance immunosuppression (11/29, 38%) 
(including mycophenolate (7/16), IVIg (3/7) and rituximab (1/6) 
(P=0.016)).
Seven out of fifty-nine patients switched maintenance immu-
nosuppression treatment (figure 2E) due to concerns of cumu-
lative dose toxicity in one (cyclophosphamide), intolerable side 
effects of nausea and vomiting in one (azathioprine) and treat-
ment failure of the initial agent in five (mycophenolate n=2, 
methotrexate n=2, azathioprine n=1) patients. Two patients 
experienced a relapse following a switch in treatment, with one 
out of seven (14%) experiencing treatment failure.
Seven patients were treated with azathioprine. Three patients 
experienced intolerance with prominent nausea, prompting 
cessation. Four patients received azathioprine for ≥6 months 
and two out of four were treatment failures (see online supple-
mentary figure 1B and appendix 2). Two patients were treated 
with methotrexate. One out of two patients reported nausea 
and fatigue but continued treatment. Both patients experienced 
breakthrough relapses despite adequate dose and duration of 
treatment. Another two patients were treated with cyclophos-
phamide, with one experiencing treatment failure (see online 
supplementary table 4). Six out of fifty-nine patients received 
plasma exchange during treatment, with five patients receiving 
five exchanges following a single demyelinating episode. Only 
one patient (patient 34) received monthly plasma exchange 
over a 24-month period, but has required concomitant steroids, 
mycophenolate and rituximab to control disease activity. Seven 
out of fifty-nine patients received treatment with one or more 
immunomodulatory agents for a presumed diagnosis of MS at 
some point in their disease course (interferons n=6, glatiramer 
acetate n=3) (see online supplementary table 4).
risk factors for poor outcomes and residual disability
The average EDSS at initial presentation was higher in chil-
dren (5.6 (median 5, range 2–9.5)) than in adults (4.4 (median 
4, range 1–8.5)) (P=0.025), but was similar between the two 
age groups at latest follow-up (total cohort: 1.3 (median 1, 
range 0–5.5)) (table 1). The median EDSS at recovery for later 
episodes was higher than the median EDSS at recovery for 
earlier episodes (figure 3A, online supplementary table 5). None 
of the patients who experienced ≥7 episodes returned to an 
EDSS of 0, suggesting cumulative disability. Logistic regression 
demonstrated that patients with any ON were less likely to have 
a final EDSS of ≥2 (OR 0.15, 95% CI 0.03 to 0.85, P=0.032), 
while those who had any TM were more likely to have sustained 
residual deficits (OR 3.56, 95% CI 0.87 to 14.46, P=0.077) 
(table 3).
Forty-two per cent (25/59) of patients had no residual 
disability (figure 3B). The most common deficit was visual 
acuity loss (14/59, 24%). A further 9/59 had optic disc pallor 
on funduscopy, without visual acuity reduction. Other disability 
including sensory (9/59, 15%), motor (8/59, 14%), cognitive 
(7/59, 12%) and sphincter (6/59, 10%) dysfunction was also 
present. Epilepsy was rare (2/59, 3%) and limited to two children 
with seizures as a prominent part of their early presentation who 
went on to develop refractory seizures, which were difficult to 
control even with multiple antiepileptic agents. Recovery status 
was available in 190/218 episodes (figure 3C). The proportion of 
episodes with complete recovery was higher when the presenting 
phenotype was ADEM, BON and UON, and lower with TM (see 
online supplementary table 6).
dIsCussION
This study identified a female predominance, and over 70% of 
patients in this Australasian cohort were Caucasian. Coexistent 
autoimmunity in this cohort was lower than reported for AQP4 
antibody-positive patients. Demyelinating episodes in almost 
half the patients were preceded by an infectious prodrome. BON 
was the most common initial presentation and UON was the 
most frequent phenotype throughout the disease course. Optic 
disc swelling was common as we have previously reported,6 23 
and suggestive of MOG antibodies. ADEM was prominent in 
children,24 while TM was more common in adults. It is addition-
ally likely that a proportion of children previously classified as 
multiphasic DEM (MDEM) have MOG antibodies.25 26 Brain-
stem presentations classically recognised in AQP4 antibody-pos-
itive disease,27 were present in some patients and have also been 
recently reported.28 MOG antibody-associated seizures have 
been described in a few adults,29 and we identified two such chil-
dren. Only a minority of patients in our cohort fulfilled revised 
McDonald criteria for MS. Other paediatric cohorts have simi-
larly identified subgroups of MOG antibody-positive children 
with relapsing demyelination including AQP4 antibody-negative 
NMOSD, MDEM and recurrent ON.30 Sepulveda et al demon-
strated that only a quarter of adult patients they studied were 
diagnosed as NMOSD, with the majority of their MOG anti-
body-positive patients having isolated optic neuritis, and a much 
lower frequency having TM, which were similar to the findings 
in our cohort.31 Interestingly, a recent study32 identified a few 
patients with MOG antibodies who had clinically definite MS 
and fulfilled revised McDonald criteria. These patients had brain-
stem and spinal cord involvement with a severe disease course, 
numerous relapses, failure of immunomodulatory therapy and a 
favourable response to plasma exchange in some. This finding 
emphasises that there remains diversity in phenotypes associated 
with MOG antibody-associated demyelination, and that some 
overlap may be present between patients with clinically definite 
MS and MOG antibodies.
A large proportion of patient MRIs in this study showed 
no brain lesions, and only a small percentage fulfilled revised 
McDonald criteria. This contrasts with MS radiology, and may 
be helpful diagnostically. Optic nerve and brain radiology may 
discriminate between MOG antibody-associated demyelination, 
AQP4 antibody-positive NMOSD and MS.23 33 Indeed, a recent 
study has identified that the presence of large ‘fluffy’ lesions or 
three or fewer brain lesions is suggestive of MOG antibody-asso-
ciated demyelination.34
This study identified that patients with relapsing MOG 
antibody-associated demyelination are steroid responsive, but 
frequently relapse at daily prednisone doses <10 mg, within 
the first 2 months of steroid cessation, and with a rapid taper. 
This data provides further detail to corroborate previous reports 
on poststeroid relapses by our group6 as well as a European 
cohort.11 A number of patients had an extremely rapid return 
to baseline within 48 hours following steroid initiation (personal 
observation). Some patients on maintenance low-dose predni-
sone alone had a relapse-free course, suggesting this is effective 
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in sustaining remission, but the significant long-term metabolic 
and bone health-related adverse effects warrant caution. A 
subgroup of MOG antibody-positive patients remained relapse 
free on no immunotherapy for a long time after initial treatment 
with steroids, and had a relapse many years later.
This study identified improvement in ARRs with most immu-
notherapies evaluated. Treatment failure rates were lowest with 
maintenance oral prednisone and rituximab. Weaning doses of 
IVIg and prednisone as well as B-cell repopulation after ritux-
imab frequently resulted in relapses, further emphasising the 
effect of immune therapy in relapse prevention in this condition. 
In relapsing MOG antibody-positive patients needing rituximab, 
regular CD19 monitoring and proactively redosing a brittle 
patient in the event of B-cell repopulation might reduce the inci-
dence of repopulation relapses, as demonstrated in NMOSD.35 36 
A recent study evaluating 67 patients with NMOSD suggested 
mycophenolate showed efficacy and was well tolerated in 
patients with NMOSD regardless of AQP4 antibody status; 
however, this cohort only included five MOG antibody-positive 
patients.37 In our cohort, mycophenolate also appeared to have 
effect, but treatment failure rates were higher and relapses were 
often associated with steroid taper suggesting the steroid was 
producing the benefit in these patients. Switching maintenance 
immunotherapy following treatment failure on the initial agent 
significantly reduced relapse rates, supporting the need for flex-
ibility in management.
MOG antibody-associated demyelination has been suggested 
to have a more favourable prognosis compared with AQP4 
antibody-associated disease.5 7 38 39 The median EDSS at acute 
presentation in this relapsing cohort was 5 and at latest clin-
ical follow-up was 1, suggesting that the majority of patients did 
have a good outcome. We showed that the severity of the first 
episode appeared to be worse than relapses—this could be due 
to either patients presenting earlier or being on immunotherapy 
at the time of relapse, or potentially due to the nature of the 
disease process. Interestingly, having ON at some point in the 
disease course appeared to be protective with regard to sustained 
disability. In contrast, there was a trend in patients with TM 
Figure 3 Recovery and outcomes in relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination. (a) Median eDss and range of 
the cohort at the nadir and at recovery after each demyelinating episode. (B) percentage of patients with residual disability in a particular domain. (c) 
Recovery status of all clinical episodes based on clinical phenotype. aDeM, acute disseminated encephalomyelitis; BON, bilateral optic neuritis; e, episode; 
eDss, expanded Disability status scale; cyclo, cyclophosphamide; IVIg, intravenous immunoglobulin; LeTM, longitudinally extensive transverse myelitis; pLeX, 
plasma exchange; RTX, rituximab; TM, transverse myelitis; UON, unilateral optic neuritis.
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towards having more severe residual deficits. We showed only 
42% of patients in the total cohort had no residual disability, 
suggesting that EDSS measures may underestimate non-motor 
deficits, and that residual disability in this condition is common. 
A recent study, mainly in adults, by Jarius et al11 similarly high-
lights the potential for serious disability in these patients. While 
some studies show early evidence that persistent MOG antibody 
seropositivity may be associated with relapsing disease,40 larger 
numbers of patients followed up for longer periods of time are 
required to clarify the therapeutic and prognostic implications of 
MOG antibody seropositivity in a clinical setting.
Our data suggests that in relapsing MOG antibody-positive 
patients, a prolonged steroid taper may reduce the chance of 
early relapses and provide a good maintenance option, with 
close monitoring during and after steroid cessation. Having a 
relapse plan with readily accessible steroids for typical symp-
toms has also been used locally in some patients. In the event 
of a relapse, after acute treatment, prophylaxis with low-dose 
prednisone or monthly IVIg would be reasonable, with myco-
phenolate or rituximab as a next step. In the event of a patient 
having TM, more aggressive immunosuppressive therapy such as 
rituximab from an early stage would be indicated if the patient 
is not showing early improvement with steroids. Second-line 
agents such as mycophenolate may take months to reach their 
full efficacy, thus corticosteroids should not be rapidly weaned 
when adding on or switching therapeutic agents.
Limitations of this study include the retrospective design, the 
small number of patients in some treatment groups and the fact 
that some patients were on multiple therapeutic agents simul-
taneously. Some regression to the mean with ARRs cannot be 
excluded. Additionally, indication bias which is inherently 
present in observational studies, is acknowledged. Future studies 
with accumulated larger cohorts should identify clinical and 
radiological characteristics which may confound treatment 
assignment and combine them into a propensity score for use 
in multivariable models in order to mitigate some of the effects 
of indication bias. While we were able to perform multivariable 
logistic regression when comparing paediatric and adult patients 
in our cohort, due to relatively small numbers of patients in some 
of the treatment groups, we could not apply this when analysing 
our therapeutic data. Nevertheless, our current study systemati-
cally evaluates treatment responses in both children and adults in 
the largest reported cohort of relapsing MOG antibody-positive 
patients to date with an average of 5 years of follow-up, and 
provides important information on disease course, therapeutic 
efficacy and outcomes.
Given the emerging literature on the clinical and radiological 
phenotype and pattern of treatment response, we believe this 
condition warrants designation as a separate clinical entity from 
MS and NMOSD. We recommend the terminology ‘MOG anti-
body-associated demyelination’ as a more accurate syndromic 
diagnosis. Given the high pretest probability of MOG anti-
body-positivity in children, we believe that it is reasonable to 
test for MOG antibodies in all childhood-onset demyelination, 
particularly if relapsing. In adults, we recommend that MOG 
antibody-testing could be reasonably restricted to patients with a 
clinical and radiological phenotype atypical for MS, particularly 
in the event of isolated or recurrent ON. The clinical spectrum 
in adults additionally appears to be broader than simply AQP4 
antibody-negative patients with NMOSD.
In conclusion, ON is the dominant manifestation of MOG 
antibody-associated demyelination, but there is a wide clinical 
spectrum. Relapsing patients are often steroid responsive, but 
vulnerable to relapses on tapering or withdrawal. Consider-
ation should be given to early secondary prevention treatment 
strategies that may include maintenance corticosteroids, IVIg or 
immunosuppression with mycophenolate or rituximab.
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